Dr. Nathalie Varoqueaux is a medical doctor specialized in hematology and holds a PhD in Cell and Molecular Biology from Université Paris VI Pierre et Marie Curie. She has held various leadership positions in pharmaceutical companies such as Roche, Alexion, and AstraZeneca, in medical affairs, business development, and pharmacovigilance. Since May 2020, she has been the Medical Director of Amgen France. She also serves as Vice-President of ARIIS (Alliance for Research and Innovation in Health Industries), Vice-President of the Research and Innovation Committee at LEEM, and is a board member of the Artificial Intelligence and Cancer Consortium.
Amgen, a pioneer in medical biotechnology since 1980, is the world’s largest independent biotech company. Present in France since 1990, Amgen France employs nearly 380 people and provides innovative treatments for cancer, cardiovascular, inflammatory, kidney, and rare diseases. With around 20 medicines and major clinical research activity, France is one of Amgen’s key R&D hubs, with over €22 million invested annually in health innovation.
